2023 FDA approvals: unprecedented volume at moderate value.
作者信息
Baedeker Mathias, Ringel Michael S, Möller Clemens C
出版信息
Nat Rev Drug Discov. 2024 Feb;23(2):98. doi: 10.1038/d41573-024-00011-9.
PMID:38233681
Abstract
摘要
相似文献
1
2023 FDA approvals: unprecedented volume at moderate value.
Nat Rev Drug Discov. 2024 Feb;23(2):98. doi: 10.1038/d41573-024-00011-9.
2
FDA new drug approvals in Q1 2021.
Nat Rev Drug Discov. 2021 May;20(5):334. doi: 10.1038/d41573-021-00067-x.
3
2023 FDA approvals.
Nat Rev Drug Discov. 2024 Feb;23(2):88-95. doi: 10.1038/d41573-024-00001-x.
4
2022 FDA approvals.
Nat Rev Drug Discov. 2023 Feb;22(2):83-88. doi: 10.1038/d41573-023-00001-3.
5
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
JAMA Oncol. 2019 Jun 1;5(6):887-892. doi: 10.1001/jamaoncol.2019.0167.
6
Study bolsters concerns about US FDA accelerated drug approvals.
Lancet Oncol. 2024 May;25(5):543. doi: 10.1016/S1470-2045(24)00205-5. Epub 2024 Apr 12.
7
2011 FDA drug approvals.
Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. doi: 10.1038/nrd3657.
8
Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.
Nat Rev Clin Oncol. 2022 Apr;19(4):217-218. doi: 10.1038/s41571-022-00605-5.
9
Significant FDA approvals in 1999.
Am Fam Physician. 2000 Apr 15;61(8):2531-3.
10
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Int J Technol Assess Health Care. 2020;36(1):20-28. doi: 10.1017/S0266462319000813. Epub 2019 Nov 28.
引用本文的文献
1
Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.
Innovation (Camb). 2025 Jan 14;6(4):100801. doi: 10.1016/j.xinn.2025.100801. eCollection 2025 Apr 7.
2
TarKG: a comprehensive biomedical knowledge graph for target discovery.
Bioinformatics. 2024 Oct 1;40(10). doi: 10.1093/bioinformatics/btae598.
Zotero 插件